Attachment II - F^ge 4 
9209-027* (M) 
9209-028* (M) 
9209-029 (M) 
9209-030 (M) 
9403-031/9209-031 (T) 
9209-032 (M) 
9209-033 (T) 
9212-034* (T) 
Schuening, Friedrich G.; Fred Hutchinson Cancer Research Center, University of Washington, Seattle, 
Washington; A Phase I/II Study of PEXY321, a rhGM-CSF/rhIL-3 Fusion Protein or rhG-CSF, for the 
Mobilization of Peripheral Blood Stem Cells for Autologous Stem Cell Transplantation. 
RAC Approval: 9-14-92/NTH Approval: 2-5-93 
Minor Modification: 2-25-94 
Schuening, Friedrich G.; Fred Hutchinson Cancer Research Center, University of Washington, Seattle, 
Washington; Evaluation of the Use of Recombinant Human G-CSF Stimulated Peripheral Blood Progenitor 
Cell Supplementation in Autologous Bone Marrow Transplantation in Patients with Lymphoid Malignancies. 
RAC Approval: 9-14-92/NIH Approval: 2-5-93 
Minor Modification 2-25-94 
CLOSED: 2-25-94 (Merged with protocol # 9209-027) 
Schuening, Friedrich G.; Fred Hutchinson Cancer Research Center, University of Washington, Seattle, 
Washington; A Trial of G-CSF Stimulated Peripheral Blood Stem Cells for Engraftment in Identical Twins. 
RAC Approval: 9-14-92/NIH Approval: 2-5-93 
CLOSED: Protocol Never Initiated 
Deisseroth, Albert B.; University of Texas MD Anderson Cancer Center, Houston, Texas; Use of Retroviral 
Markers to Identify Efficacy of Purging and Origin of Relapse Following Autologous Bone Marrow and 
Peripheral Blood Cell Transplantation in Indolent B Cell Neoplasms (Follicular Non-Hodgkin’s Lymphoma 
or Chronic Lymphocytic Leukemia) Patients. 
RAC Approval: 9-14-92/NIH Approval: 12-2-93 
Minor Modification: 11-3-93 
Minor Modification: 11-18-93 
Roth, Jack A.: The University of Texas MD Anderson Cancer Center. Houston. Texas: Clinical Protocol 
for Modification of Oncogene and Tumor Suppressor Gene Expression in Non-Small Cell Lung Cancer 
NSCLC). 
9209-031/ RAC Approval of Original Protocol: 9-15-92/ 
RAC Approval of Original Protocol Withdrawn 12-3-93 
9403-031/ RAC Approval of Resubmitted Protocol: 3-4-94/ 
NTH Approval of Resubmitted Protocol: Pending 
Brenner, Malcolm K.; St. Jude Children’s Research Hospital, Memphis, Tennessee; A Phase II Trial of the 
Baxter Neuroblastoma Bone Marrow Purging System Using Gene Marking to Assess Efficacy. 
RAC Approval: 9-15-92/NTH Approval: 2-5-93 
Lotze, Michael T. and Rubin, Joshua T.; University of Pittsburgh, Pittsburgh, Pennsylvania; Gene Therapy 
of Cancer. A Pilot Study of IL-4 Gene Modified Antitumor Vaccines. 
RAC Approval: 9-15-92/NIH Approval: 2-5-93 
Crystal, Ronald G.; New York Hospital-Cornell Medical Center; A Phase I Study, in Cystic Fibrosis 
Patients, of the Safety, Toxicity, and Biological Efficacy of a Single Administration of a Replication Deficient, 
Recombinant Adenovirus Carrying the cDNA of the Normal Human Cystic Fibrosis Transmembrane 
Conductance Regulator Gene in the Lung. 
RAC Approval: 12-3-92/NTH Approval: 4-16-93 
Minor Modification: 5-17-93 
Minor Modification: 10-8-93 
Minor Modification: 11-29-93 
Minor Modification: 2-4-94 
Recombinant DNA Research, Volume 20 
[95] 
